[Seite 144↓]


1. Anderson KM, Seed T, Meng J, Ou D, Alrefai WA, Harris JE: Five-lipoxygenase inhibitors reduce PANC-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid. Anticancer-Res 1998, 18: 791-800

2. Anderson WB, Thomas TB, et al.: Retinoic acid modulation of c-AMP-dependent and calcium. Dermatologica 1984; 169: 221

3. Andrén-Sandberg A, Borg S, Dawiskiba I, Ferno M Estrogen receptors and estrogen binding protein in pancreatic cancer. Digestion 1982: 25: 12

4. Appel KE, Gorsdorf S, et al.: Metabolic denitrosation of N-nitrosamines: mechanisms and biological consequences, IARC-Sci-Publ 1991: 105: 351-357

5. Appel MJ, Garderen-Hoetmer A, et al.: Effects of dietary linoleic acid on pancreatic carcinogenesis in rats and hamsters, Cancer-Res 1994: 54: 2113-2120

6. Appel MJ, Roverts G, et al.: Inhibitory effects of micronutrients on pancreatic carcinogenesis in azaserine treated rats, Carcinogenesis 1991: 12: 2157-2161

7. Appel MJ, Woutersen RA: Effects of linoleic acid and fish oil on pancreatic carcinogenesis in rats, Proc-Am-Assoc-Cancer-Res 1994: 35: 826

8. Appel MJ, Woutersen RA: Effects of linoleic acid and fish oil on pancreatic carcinogenesis, Carcinogenesis 1994: 138: 826

9. Appel MJ, Woutersen RA: Effects of dietary fish oil (MaxEPA) on N-nitrosobis-2-oxopropyl-amin (BOP) induced pancreatic carcinogenesis in hamsters. Cancer Lett 1995; 94(2): 179-189

10. Appel MJ, Woutersen RA: Dietary fish oil (MaxEPA) enhances pancreatic carcinogenesis in azaserine treated rats. Br J Cancer 1996, 73(1): 36-43

11. Appel MJ, Woutersen RA: Effects of dietary beta carotene and selenium on initiation and promotion of pancreatic carcinogenesis in azaserine treated rats, Carcinogenesis 1996: 17: 1411

12. Ara G, Teicher BA: Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins-Leukotrienes-Essent-Fatty-Acids 1996, 54: 3-16

[Seite 145↓]

13. Arbuck SG: Overview of chemotherapy for pancreatic cancer . Int J Pancreatol 1990; 7: 209-32.

14. Arias Diaz J, Vara E, et al.: Local production of oxygen free radicals and nitric oxide in rat diaphragm during sepsis: effects of pentoxifylline and somatostatine, Eur-J-Surg 1997; 163: 619-625

15. Arnold R, Frank M, et al.: Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues, Digestion 1994: 55(Suppl3): 107-113

16. Arnold R, Lankisch PG: Somatostatin and the gastrointestinal tract, Clin-Gastroenterol 1980; 9: 733-753

17. Asano N, Manabe T, et al.: Effect of synthetic protease inhibitor on the oncogenesis of pancreatic cancer in hamsters: study on pancreatic endocrine cells and free radicals, Nippon-Geka-Hokan 1991: 60: 424-434

18. Bakker WH, Krenning EP, et al.: In vivo application of [111IN-DTPA-D-PHE1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life-Sci 1991: 49: 1593-1601

19. Bakkevold KE, Petterson A, Arnesjo B, Espehaug B Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990: 77: 725-30

20. Bartsch H, Hietanen E, et al.: Carcinogenic nitrosamines: free radical aspects of their action, Free-Radic-Biol-Med 1989: 7: 637-644

21. Bauer W, Briner U, et al.: SMS201-995: A very potent and selective octapeptide analog of somatostatin with prolonged action, Life-Sci 1982: 31: 1133-1140

22. Beauchamp C, Fridovich I: Superoxide dismutase: improved assay and an assay applicable to acrylamide gels, J-Anal-Bi-2ochem 1971: 44: 276-287:

23. Beger HG: Prognosefaktoren beim Pankreaskarzinom, Langenbecks-Arch-Chir 1995: 380: 131-132

24. Beger HG, Büchler MW, Friess H Chirurgische Ergebnisse und Indikation zu adjuvanten Maßnahmen beim Pankreaskarzinom. Chirurg 1994: 65: 246

25. Bell GI, Reisine T: Molecular biology of somatostatin receptors, Trends-Neurosci 1993: 16: 34-39

[Seite 146↓]

26. Ben-Efraim S, Bonta IL: Modulation of antitumour activity of macrophages by regulation of eicosanoids and cytokine production, Int-J-Immunopharmacol 1994: 16: 397-399

27. Benzie IF: Lipid peroxidation: a review of causes, consequences, measurement and dietary influences, Int-J-Food-Sci-Nutr 1996: 47: 233-261

28. Birt DF, Julius AD, et al.: Comparison of the effects of dietary beef tallow and corn oil on pancreatic carcinogenesis in the hamster model, Carcinogenesis 1990: 11: 745-748

29. Birt DF, Julius AD, et al.: Enhancement of BOP-induced pancreatic carcinogenesis in selenium-fed Syrian golden hamsters under specific dietary conditions, Nutr-Cancer 1988: 11: 21-33

30. Birt DF, Julius AD, et al.: Enhancement of pancreatic carcinogenesis in hamsters fed a high fat diet ad libitum and at a controlled calorie intake, Cancer 1989: 49: 5848-5851

31. Bruzeau P, Vale W, et al.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone, Science 1973: 179: 77-79

32. Brigellius-Flohé, R: Tissue-specific functions of individual glutathion peroxidases. Free-Rad-Biol-Med 1999; 27: 951-965

33. Büchler MW, Friess H, et al.: Role of octreotide in the prevention of postoperative complications following pancreatic resection, Am-J-Surg 1992: 163: 124-131

34. Buscail L, Delesque N, et al.: Stimulation of tyrosin phosphatase and inhibition of cell proliferation by somatostatin analogs: mediation by human somatostatin receptor subtypes sstr1 and sstr2, Proc-Natl-Acad-Sci-USA 1994: 91: 2315-2319

35. Buscail L, Esteve JP, et al.: Inhibition of cell proliferation by the somatostatin analog RC-160 is mediated by somatostatin receptor subtypes sstr2 and sstr5 through different mechanisms, Proc-Natl-Acad-Sci-USA 1995: 92: 1580-1584

36. Buyn T, Dudeja P, Harris JE, Ou D, Seed T, Sawlani D, Meng J, Bonomi P, Anderson KM: A 5-Lipoxygenase inhibitor at micromolar concentration raises intracellular calcium in U937 cells prior to their physiologic cell death. Prostaglandins-Leukotrienes-Essent-Fatty-Acids 1997: 56: 69-77

[Seite 147↓]

37. Cai J, Jiang WG, et al.: Inhibition of vascular endothelial cell motility and angiogenesis by g-linolenic acid, Prostaglandins-Leucotrienes-Essent-Fatty-Acids 1997: 75: 247

38. Cai RZ, Szoke B, et al.: Synthesis and biological activity of highly potent octapeptide analogs of somatostatin, Proc-Natl-Acad-Sci-USA 1986: 83: 1896-1900

39. Cameron E, Pauling L, et al.: Ascorbic acid and cancer: a review. Cancer-Res 1979; 39: 663-681

40. Canobbio L, Boccardo F, et al.: Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM23014, Gastroenterology 1992: 69: 648-650

41. Cascinu S, Del Ferro E, et al.: A randomized trial of octreotide vs best supportive care only in advanced cancer patients refractory to chemotherapy, Br-J-Cancer 1986: 46: 2954-2957

42. Chan AC, Wagner M, et al.: Vitamin E erhöht die Expression von Phospholipase A2, die Freisetzung von Arachidonsäure und die Enzymmassen von Cyklooxygenase in Endothelzellen. Akt-Ernähr-Med 1998; 23: 152-159

43. Cheeseman KH, Emery S, et al.: Studies on lipid peroxidation in normal and tumor tissues. Biochem-J 1988; 250: 247-252

44. Clerk P, Bensaadi N, et al.: Lipid-dependent proliferation of pancreatic cancer cell lines, Cancer-Res 1991: 51: 3633-3638

45. Cogrel P, Morel I, et al.: The relationship between fatty acid peroxidation and a-tocopherol consumption in isolated normal and transformed hepatocytes. Lipids 1993; 28: 115-119

46. Comaru-Schally M, Schally AV (1988) LH-RH antagonists as adjuncts to somatostatin analogs in the treatment of pancreatic cancer. In: Lunefeld B, Vichery B, eds. International symposium on GN-RH analogues in cancer and human reproduction. Geneva: MTP Press

47. Crown J, Casper ES, Botet J, Murray P, Kelsen DP: Lack of efficacy of high-dose leudovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9: 1682-1686.

[Seite 148↓]

48. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF: A phase III trial on the therapy of advanced pancreatic carcinoma Evaluation of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65: 2207-12

49. Damtew B, Spagnuolo PJ: Tumor cell-endothelial cell interactions: evidence for roles for lipoxygenase products of arachidonic acid in metastasis. Prostaglandins-Leukotrienes-Essent-Fatty-Acids 1997, 56: 295-300

50. Davies GR, Rampton DS: Eicosanoids: role in gastrointestinal inflammation and cancer, Eur-J-Gastroenterol-Hepatol 1997: 9: 1033-1044

51. Davies N, Kyaston H, et al.: Octreotide, the reticuloendothelial system and liver metastasis, Gut 1995: 36: 610-614

52. Davies N, Kyaston H, et al.: Octreotide inhibits the growth and development of three types of experimental liver metastases, Br-J-Surg 1995: 82: 840-843

53. De Caprio JA, Mayer RJ, Gonin R, Arbuck SG: Fluorouracil and high-dose leucovorin in preiously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991: 9: 2128-2133.

54. De Caterina R, Cybulsky MI, et al.: DHA reduces cytokine induced expression of proatherogenic and proinflammatory proteins in human endothelial cells, Atheroscler-Thromb 1994: 14: 1829

55. De Caterina R, Cybulsky MI, et al.: w-3 fatty acids and endothelial leucocyte adhesion molecules, Prostaglandins-Leucotrienes-Essent-Fatty-Acids 1995: 52: 191-195

56. De Haan JB, Cristiano F, et al.: Elevation in the ratio of Cu/Zn superoxide dismutase to glutathion peroxidase activity induces features of cellular senescene and this effect is mediated by hydrogen peroxide. Human-Molec-Genet 1996; 5: 283-292

57. Ding XZ, Kuszynski Ca, El-Metwally TH, Adrian TE: Lipoxygenase inhibition induced apoptosis, morphological changes and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Comm 1999; 266: 392-399

58. Dobelbower RR Jr, Konski AA, Merrick HW, Bronn DG Intraoperative electron beam radiation therapy (IOEBRT) for carcinoma of the exocrine pancreas. Int J Radiat Oncol Biol Phys 1991: 20: 113

[Seite 149↓]

59. Dutoit PJ, Vanaswegen CH, et al.: The effect of essential fatty-acids on growth and urokinase-type plasminogen-activator production in human prostate DU-145 cells, Prostaglandins-Leucotrienes-Essent-Fatty-Acids 1996: 55: 173-177

60. Ebert M, Friess H, et al.: Role of octreotide in the treatment of pancreatic cancer, Digestion 1994: 55(Suppl1): 48-51

61. Eichholzer M, Stähelin HB: Antioxidative Vitamine und Krebs – eine Übersicht. Akt-Ernähr-Med 1994; 19: 2-11

62. Elmadfa I, König JS: Vitamine in der Ernährung des Tumorkranken. Akt-Ernähr-Med. 1992; 17: 320-325

63. Eskelson CD, Odeleye OE, et al.: Modulation of cancer growth by vitamin E and alcohol, Alcohol-Alcohol 1993: 28: 117-125

64. Falconer JS, Ross JA, et al.: Effect of EPA and other fatty acids on the growth in-vitro of human pancreatic-cancer cell lines, Br-J-Cancer 1995: 69: 826-832

65. Fazeny B, Baur M, et al.: Octreotide combined with goserelin in the therapy of advanced pancreatic cancer – results of a pilot study and review of the literature, J-Cancer-Res-Clin-Oncol 1997: 123: 45-52

66. Fearon KCH, Falconer JS, et al.: An open label phase i/ii dose-escalation study of the treatment of pancreatic cancer using lithium-g-linolenate, Anticancer-Res 1996: 16: 867-874

67. Fisher WE, Muscarella P, et al.: Expression of the somatostatin receptor subtype-2 predicts response of human pancreatic cancer to octreotide. Surgery 1996: 120: 234-241

68. Flagg EW, Coates RJ et al.: Epidemiologic studies of antioxidants and cancer in humans. J-Am-Coll-Nutr 1995; 14: 419-427

69. Frei B, England L, et al.: Ascorbate is an outstanding antioxidant in human blood plasma. Proc-Natl-Acad-Sci 1989; 86: 6377-6381

70. Fridovich I: Quantitative aspects of the production of superoxide anion radical by milk xanthine oxidase, J-Biol-Chem 1970: 245: 4053-4057

71. Friess H, Büchler MW, et al.: Low dose octreotide treatment is not effective in patients with advanced pancreatic cancer, Pancreas 1993: 8: 540-545

[Seite 150↓]

72. Friess H, Büchler MW, et al.: Treatment of advanced pancreatic cancer with high dose octreotide, Int-J-Pancreatol 1993: 14: 290-291

73. Friess H, Isenmann R, et al.: Die Prognose des Pankreaskarzinoms, Ther-Umschau 1996: 53: 401-407

74. Gastrointestinal Tumor study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751-755.

75. Gattani A, Mandeli J, Chesser MR, Bruckner HW: An active biochemical modulation regimen for advanced adenocarcinoma of the pancreas. Proc Am Soc Clin 1992: 11: 193.

76. Gillespie J, Poston GJ, et al.: Human pancreatic cancer cell lines do not express receptors for somatostatin, Br-J-Cancer 1992: 66: 483-487

77. Gudjonsson B Cancer of the pancreas. 50 years of surgery. Cancer 1987: 60: 2284

78. Guliana JM, Guillausseau PJ, Caron J, Siame-Mourot C et al Effects of short term subcutaneous administration of SMS 201-995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma. Horm Metab Res 1989: 21: 584-6

79. Hahnel D, Beyer K et al.: Inhibition of peroxyl radical-mediated lipid oxidation by plasmalogen phospholipids and a-tocopherol. Free-Radic-Biolo-Med 1999; 27: 1087-1094

80. Hall PA, Lemoine NR: Models of pancreatic cancer, Cancer-Surv 1993: 16: 135-155

81. Hamers MN, Ross D: Oxidative stress in human neutrophil granulocytes: host defence and self defence, in: Siess H, editor: Oxidative stress, New York Academic Press 1985: 351-381

82. Hasler CM, Bennink MR, et al.: Inihibition of gap junction-mediated intercellular communication by a-linolenate, Am-J-Physiol 1991: 261: 161-168

83. Hawkins RA, Sangster K, et al.: Apoptotic death of pancreatic cancer cells induced by polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism, J-Pathol 1998: 185: 61-70

[Seite 151↓]

84. Hayashi Y, Fukushima S, et al.: Anticancer activity of free g-linolenic acid on AH-109a rat hepatoma cells and the effects of serum-albumin on anticancer activity of g-linolenic acid in vitro, J-Pharmacobiodynam 1990: 13: 705-711

85. Hierowski MT, Liebow C, du Sapin K, Schally AV Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS-Lett 1985: 179 (2): 252-6

86. Hennig B, Lipke D, et al.: Role of fatty-acids and eicosanoids in modulating proteoglycan metabolism in endothelial-cells, Prostaglandins-Leucotrienes-Essent-Fatty-Acids 1995: 53: 315-324

87. Hermanek P, Scheibe O, Spiessl B, Wagner G: TNM Klassifikation maligner Tumoren. Springer, Berlin – Heidelberg – New York 1992

88. Herrington MK, Permert J, et al.: Effects of high fat diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster, Carcinogenesis 1993: 14: 1021-1026

89. Herrington MK, Gasslander T, et al. Effects of high-fat diet and cholecystokinin receptor blockade on promotion of pancreatic ductal cell tumors in the hamster, Nutr-Cancer 1997: 28: 219-224

90. Hill GE, Whitten CW: The role of the vascular endothelium in inflammatory syndromes, atherogenesis, and the propagation of disease, J-Cardiothorac-Vasc-Anesth 1997: 11: 316-321

91. Hollan S: Free radicals in health and disease, Haematologia-Budap 1995: 26: 177-189

92. Holmes RS, van de Berg LJ: Aldehyde dehydrogenases, aldehyde oxidase and xanthine oxidase from baboon tissue, Alcohol 1986: 3: 205-214

93. Horrobin DF: Essential fatty acids, lipid peroxidation, and cancer, In: Horrobin DF (ed. ): w-6 Essential fatty acids, New York, Wiley-Liss 1990: 351-378

94. Hosono J, Narita T, Kimura N, Sato M, Nakashio T, Kasai Y, Nonami T, Nakao A, Takagi H, Kannagi R: Involvement of adhesion molecules in metastasis of SW1990, human pancreatic cancer cells. J-Surg-Oncol 1998, 67: 77-84

[Seite 152↓]

95. Hoyer D, Bell GI, et al.: Classification and nomenclature of somatostatin receptors, Trends-Pharmacol-Sci 1995: 16: 86-88

96. Hubbard NE, Erickson KL: Effect of dietary linoleic-acid level on lodgement, proliferation and survival of mammary tumor metastases, Cancer-Lett 1989: 44: 117

97. Hubbard NE, Erickson KL: Role of dietary oleic-acid in linoleic-acid – enhanced metastasis of a mouse mammary tumor, Cancer-Lett 1991: 56: 165-171

98. Hughes O, Sharman V, et al.: Somatostatin and the treatment of pancreatic cancer, Ann-R- Coll-Surg-Engl 1994: 76: 354

99. Huguier M, Samama G, et al.: Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone), Am-J-Surg 1992: 164: 348-352

100. Ihse I, Andersson R, et al.: Pancreatic pain: is there a medical alternative to surgery?, Digestion 1993: 54(Suppl2): 30-34

101. Ishii H, Okada S, et al.: Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy, Pancreas 1996: 12: 267-271

102. Isliker H, Weiser H, et al.: Stabilization of rat heart mitochondria by a-tocopherol in rats. Int-J-Vit-Nutr-Res 1996; 67: 91-94

103. Janero DR: Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury, Free-Radic-Biol-Med 1990: 9: 515-540

104. Jiang WG, Bryce RP, et al.: Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications, Crit-Rev-Oncol-Hematol 1998: 27: 179-209

105. Jiang WG, Bryce RP, Mansel RE: Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumor cells. Prostaglandins-Leukotrienes-Essent-Fatty-Acids 1997, 56: 307-316

106. Jiang WG, Hiscox S, et al.: Inhibition of invasion and motility of human colon cancer cells by g-linolenic-acid, Br-J-Cancer 1995: 71: 744-752

107. Jiang WG, Hiscox S, et al.: Regulation of the expression of E-cadherin on human cancer cells by g-linolenic acid, Cancer-Res 1995: 55: 5043-5048

[Seite 153↓]

108. Jiang WG, Hiscox S, et al. Inhibition of membrane ruffling and ezrin translocation by g-linolenic acid, Int-J-Oncol 1996: 9: 279-284

109. Jiang WG, Hiscox S, et al. Regulation of nm23 expression by n-6-PUFA´s, Br-J-Cancer 1997: 77: 731-738

110. Jimenez de Asua L, Otto AM, Lindgren JA, Hammarstrom S: The stimulation of the initiation of DNA synthesis and cell division in Swiss mouse 3T3 cells by prostaglandin F2a requires specific functional groups in the molecule. J-Biol-Chem 1983; 258: 8774-8780

111. Johanning GL: Modulation of breast cancer cell adhesion by unsaturated fatty acids, Nutrition 1996: 12: 810-816

112. Johanning GL, Lin TY: Unsaturated fatty-acid effects on human breast-cancer cell-adhesion, Nutr-Cancer 1995: 24: 57-66

113. Jones JL, Clemmons DR Insulin-like growth factors and their binding proteins: Biological actions. Endocrine Reviews 1995: 16: 3

114. Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.

115. Kamthan A, Morris JC, Chesser MR, Dalton J, Mandeli J, Bruckner HW: Combined modality therapy for effective local control in stage II and III pancreatic carcinoma. Proc Am Soc Clin 1992; 11: 160.

116. Kasperk R, Ammon J, Schumpelick V: Zum Einfluß der intraoperativen Radiotherapie (IORT) auf den postoperativen Verlauf beim Pankreaskarzinom. Chirurg 1993; 64: 170-3.

117. Keating JJ, Johnson PJ, Cochrane AMG, Gazzard BG et al A prospective randomized controlled trial of tamoxifen and dyproterone acetate in pancreatic carcinoma. Br J Cancer 1989: 60: 789

118. Kappus H: Lipidperoxidation: mechanisms, analysis, enzymology and biological relevance, in: Oxidative Stress, Siess H (ed.), London Academic Press 1985: 273-310

119. Karmali RA: Eicosanoids in neoplasia, Prev-Med 1987: 16: 493-502

[Seite 154↓]

120. Kazakoff K, Cardesa T, et al.: Effects of voluntary physical exercise on high-fat diet –promoted pancreatic carcinogenesis in the hamster model, Nutr-Cancer 1996: 26: 265-279

121. Kelly DM, Benjamin IS: Pancreatic carcinoma, Ann-Oncol 1995: 6: 19-28

122. Kensler TW, Trush MA: Inhibition of phorbol ester-stimulated chemiluminescence in human polymorphonuclear leukocytes by retinoic acid and 5,6-epoxyretinoic acid. Cancer-Res 1981; 41: 216-222

123. Kent RS, Diedrich SL, et al.: Regulation of vascular prostaglandin synthesis by metabolites of arachidonic acid in perfused rabit aorta, J-Clin-Invest 1983: 72: 455

124. Kern HF, Raus K, Mollenhauer J: Fine structure of human pancreatic adenocarzinomas. In: Go VLW, Arner JD, Brooks FP, Lebenthal E, Di Maguo EP, Scheele A (Eds. ): The exocrine pancreas . Raven Press New York 1986; 621-636

125. Klempnauer J, Ridder GJ, et al.: Surgery for exocrine pancreatic cancer – who are the 5- and 10-year survivors?, Oncology 1995: 52: 353-359

126. Klijn JGH, Hoff AM, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analogue Sandostatin: a phase II study including endocrine effects, Br-J-Cancer 1990: 62: 627-630

127. Klöppel G, Held G, Morhoshi T, Seifert G: Klassifikation exokriner Pankreastumoren. Histologische Untersuchung an 167 autoptischen und 97 bioptischen Fällen. Pathologe 1982; 2: 319-328

128. Knekt P, Aromaa A, et al.: Vitamin E and cancer prevention. Am-J-Clin-Nutr 1991; 53: 283S-285S.

129. Komaki R, Wadler S, Peters T, Byhardt RW, Order S, Gallagher MJ, Herskovic A, Pederson J: High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial. Cancer 1992; 69: 2807-2812.

130. Kondo S, Toyokuni S, et al.: Persistent oxicative stress in human colorectal carcinoma, but not in adenoma. Free-Radic-Biol-Med 1999; 27: 401-410

[Seite 155↓]

131. Labbe MR, Trick KD, et al.: Dietary (n-3) fatty acids affect rat heart, liver and aorta protective enzyme activities and lipid peroxidation, J-Nutr 1991: 121: 1331-1340

132. Lafrenie R, Shaughnessy SG, et al.: Cancer cell interactions with injured or activated endothelium, Cancer-Metastasis-Rev 1992: 11: 377-388

133. Lai PBS, Ross JA, et al.: Cell-cycle arrest and induction of apoptosis in pancreatic-cancer cells exposed to EPA in-vitro, Br-J-Cancer 1996: 74: 1375-1383

134. Lamberts SWJ, Reubi JC, et al.: The role of somatostatin analogs in the control of tumor growth, Semin-Oncol 1994: 21(Suppl13): 61-64

135. Levy GN: Prostaglandin H synthases, nonsteroidal antiinflammatory drugs and colon cancer. FASEB-J 1997; 11: 234-247

136. Liebow C, Reilly C, et al.: Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase, Proc-Natl-Acad-Sci-USA 1989: 86: 2003-2007

137. Liehr RM, Melnykovych G, et al.: Growth effects of regulatory peptides on human pancreatic cancer lines PANC-1 and MIA PaCa-2, Gastroenterology 1990: 98: 1666-1674

138. Liu XH, Connolly JM, et al.: Eicosanoids as mediators of linoleic acid-stimulated invasion and type-IV-collagenase production by a metastatic human breast-cancer cell line, Clin-Exp-Metastasis 1996: 14: 145-152

139. Löhr M, Andren-Sandberg A: Cancer of the pancreas: from concordant classification to standardized treatment, Eur-J-Gastroenterol-Hepatol 1997: 9: 993-1000

140. Loeppky RN, Li YE: Nitrosamine activation and detoxication through free radicals and their derived cations, IARC-Sci-Publ 1991

141. Lok E, Jee P, et al.: The effect of different levels of dietary a-linolenic and other fatty acids on mammary-gland ductular cell-proliferation in female Swiss-Webster mice, Cancer-Lett 1995: 92: 229-234

142. Lomnitski L, bar-Natan R, et al.: The interaction between b-caroteneand lipoxygenase in plant and animal systems. Biochem-Biophys-Acta 1993; 167: 331-338

[Seite 156↓]

143. Longnecker DS: Experimental cancer of the pancreas. Curr-Opin-Gastroenterol 1991: 7: 731-738

144. Longnecker DS, Curphey TJ: Inhibition of pancreatic carcinogenesis by retinoids in azaserine-treated rats. Cancer-Res 1982; 42: 19-24

145. Longnecker DS, Memoli V, et al.: Recent results in animal models of pancreatic carcinoma: histogenesis of tumors, Yale-J-Biol-Med 1992: 65: 457-464

146. Lotan R: Mechanism of inhibition of tumor cell proliferation by retinoids. Dermatologica 1984; 169: 223

147. Lowry OH, Rosebrough NJ, et al.: Protein measurement with the folin phenol reagent, J-Biol-Chem 1951: 193: 265-275

148. Lupulescu A: Prostaglandins, their inhibitors and cancer. Prostaglandins-Leukotriens-Essent-Fatty-Acids 1996; 54: 83-94

149. Machlin LJ: Vitamin E. in: Handbook of vitamins. Marcel Dekker, New York, Basel 1991

150. Maker HS, Weiss C, et al.: Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates, J-Neurochem 1981: 36: 589-593

151. Marks F, Fürstenberger G, Müller-Decker K: Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism. Rec Res Cancer Res 1999, 151: 45-67

152. Maziere S, Cassand P, et al.: Vitamin A and apoptosis in colonic tumor cells. Int-J-Vit-Nutr-Res 1997; 67: 237-241

153. McCarthy MF: Fish-oil impede tumor angiogenesis and invasiveness by down-regulating protein-kinase c and modulating eicosanoid production, Med-Hypotheses 1996: 46: 107-111

154. Meier R: Octreotid – ein Somatostatinanalogon in der Praxis, Schweiz-Rundsch-Med-Prax 1995: 84: 325-327

155. Meijers M, Bruijntjes JP, Hendriksen EJ, Woutersen RA: Histogenesis of early preneoplastic lesions induced by N-Nitrosobis(2-oxopropyl)amine in exocrine pancreas of hamster. Int-J-Panc 1989; 4: 127-137

[Seite 157↓]

156. Meijers M, Garderen-Hoetmer A, et al.: Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters, Carcinogenesis 1990: 11: 2223-2226

157. Meryn S: Pankreaskarzinom - Epidemiologie und Risikofaktoren, Wien-Klin-Wochenschr 1994: 106: 694-697

158. Meterissian SH, Forse RA, et al. Effect of membrane free fatty-acid alterations on the adhesion of human colorectal-carcinoma cells to liver macrophages and extracellular-matrix proteins, Cancer-Lett 1995: 89: 145-152

159. Moorby CD, Stoker M, et al. HGF/SF inhibits junctional communication, Exp-Cell-Res 1995: 219: 657-663

160. Moertel CG, Frytak S, Hahn RG, MJ O´Connel, Reitemeier RJ, Rubin J, Schutt AJ, weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO, Thomas P, Nava H, Bateman J, Lokich L, Brooks J, Chaffey J, Corson JM, Zamchek N, Novak JM: Therapy of locally unresectable pancreatic carcinoma: a randomised comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5 fluorouracile), and high dose radiation + 5 fluorouracil: the gastrointestinal tumor study group. Cancer 1981; 48: 1705-10.

161. Moertel CG, Lefkopoulo M, Lipsitz St, Hahn RG, Klaassen D: Streptozocin – doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-523.

162. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 1996: 78: 633-8

163. Morgenroth K, Philippou St: Pathologie der Pankreastumoren mit und ohne Hormonproduktion. In: Kozuschek W, Paquet KJ (Hrsg.): Pankreas, Diagnostik, Therapie. Karger, Basel-München-Paris 1992: 401-419

164. Murr MM, Sarr MG, et al.: Pancreatic cancer, CA-Cancer-J-Clin 1994: 44: 304-318

165. Nakao A, Takagi H: Problems in pancreatic cancer surgery, Semin-Surg-Oncol 1998: 15: 52-56

[Seite 158↓]

166. Naundorf H, Parczyk K, Zschiesche W, Reinecke S, Büttner B, Saul GJ, Sinn B, Fichtner I: Relation of oestradiol-mediated growth stimulation with the expression of c-erb B-2 protein in xenotransplanted oestradiol-receptor-positive and negative breast carcinomas. J Cancer Res Clin Oncol 1996: 122: 14-20

167. Niedermuhlbichler M, Wiedermann CJ: Suppression of superoxide release from human monocytes by somatostatin related peptides, Regul-Pept 1992: 41: 39-47

168. Oberley TD, Oberley LW: Antioxidant enzyme levels in cancer. Histol-Histopathol 1997; 12: 525-535

169. Odeleye OE, Eskelson CE, et al.: The potential role of vitamin E in the treatment of abnormalities of immune defects in AIDS. Prog-Food-Nutr-Scie 1991; 15: 1-19

170. Odeleye OE, Watson RR, et al.: Dietary polyunsaturated fatty acid promote peroxidation and its possible role in the promotion of cancer, Adv-Exp-Med-Biol 1991: 283: 789-91

171. Ogawa T, Makino T, et al.: Promoting effects of both dietary cholesterol and cholestyramine on pancreatic carcinogenesis initiated by N-nitrosobis(2-oxopropyl)amine in Syrian golden hamsters, Carcinogenesis 1992: 13: 2047-2052

172. Ohkawa H, Ohishi N, et al.: Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction, Anal- Biochem 1979: 95: 351-358

173. Oster MW, Gray R, Panasci L, Pery MC (1986) Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-Fluorouracil, Streptozotocin, and Mitomycin-C (FSM). Cancer 1986: 57: 29

174. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocytes glutathione peroxidase, J-Lab-Clin-Med 1967: 29: 143-148

175. Pandalai PK, Pilat MJ, et al.: The effects of w-3 and w-6 fatty acids on in-vitro prostate cancer growth, Anti-Cancer-Res 1996: 16: 815-820

176. Paz-Bouza JI, Redding TW, et al.: Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone, Proc-Natl-Acad-Sci-USA 1987: 84: 1112-1116

[Seite 159↓]

177. Petkau A: Role of superoxide dismutase in modification of radiation injury, Br-J-Cancer 1987: 55(Suppl8): 87-95

178. Plescia OJ, Racis S: Prostaglandins as physiological immunoregulators. Prog-Allergy 1988; 44: 153-171

179. Plewe G, Beyer J, et al. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS201-995 in acromegaly, Lancet 1984: ii: 782-784

180. Pollak MN, Schally AV: Mechanisms of antineoplastic action of somatostatin analogs, Proc-Soc-Exp-Biol-Med 1998: 217: 143-152

181. Popescu RA, Cunningham D: Chemotherapy for advanced pancreatic cancer – some light at the end of the tunnel?, Ann-Oncol 1997: 8: 415-416

182. Poston GJ, Schally AV, et al.: Phase one study on therapeutic use, and tolerance of somatostatin analogue RC-160 in the treatment of patients with advanced pancreatic cancer, Gut 1991: 84: 178-184

183. Pour PM, Egami H, Takiyama Y: Patterns of growth and metastases of induced pancreatic cancer in relation to the prognosis and its clinical implications. Gastroenterology 1991; 100: 529-536

184. Pour PM, Runge RG, et al.: Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease, Cancer 1981: 47: 1573-1587

185. Prasad KN, Edwards-Prasad J: Expressions of some molecular cancer risk factors and their modification by vitamins. J-Am-Coll-Nutr 1990; 9: 28-34

186. Prasad KN, Sinha PK, et al.: Sodium ascorbate potentiates the gowth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc-Nati-Acad-Sci-USA 1979; 76: 829-83

187. Qin Y, Ertl T, et al.: Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate, Int-J-Cancer 1995: 60: 694-700

188. Radulovic S, Comaru-Schally AM, et al.: Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice, Pancreas 1993: 8: 88-97

[Seite 160↓]

189. Rao GN, Berk BC: Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression, Circ-Res 1992: 70: 593-599

190. Raynor K, Murphy WA, et al.: Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides, Mol-Pharmacol 1993: 43: 838-844

191. Raynor K, O´Carroll AM, et al.: Characterization of cloned somatostatin receptors SSTR4 ands SSTR5, Mol-Pharmacol 1993: 44: 385-392

192. Redding TW, Schally AV: Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones, Proc-Natl-Acad-Sci-USA 1984: 81: 248-252

193. Reich R, Martin GR: Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 1996, 51: 01-17

194. Reich R, Royce L, et al. EPA reduces the invasive and metastatic activity of malignant tumor cells, Biochem-Biophys-Res-Commun 1989: 160: 559-564

195. Reichlin S: Somatostatin, N-Engl-J-Med 1983: 309: 1495-1501

196. Remmele W: Exokrines Pankreas. In: Remmele W (Hrsg.): Pathologie Bd. 2. Springer, Berlin-Heidelberg-New York 1984: 790-845

197. Ren-Ke L, Sole MJ, et al.: Vitamin E and oxidative stress in the heart of the carciomyopathic syrian hamster. Free-radic-Biol-Med 1998; 24: 252-258

198. Reubi JC, Horisberger U, et al.: Abscence of somatostatin receptors in human exocrine pancreatic adenocarcinomas, Gastroenterology 1988: 95: 760-763

199. Reubi JC, Laissue JA: Multiple actions of somatostatin in neoplastic disease, Trends-Pharmacol-Sci 1995: 16: 110-115

200. Reubi JC, Laissue J, Krenning E, Lamberts SWJ. Somatostatin Receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem Molec Biol 1992: 43: 27

201. Rice-Evans C, Burdon R: Free radical lipid interactions and their pathological consequences. Prog Lipid Res 1993; 32: 71-110

[Seite 161↓]

202. Roebuck BD: Dietary fat and the development of pancreatic cancer, Lipids 1992: 27: 804-806

203. Roebuck BD, Longnecker DS, et al.: Carcinogen-induced lesions in the rat pancreas: effects of varying levels of essential fatty acid, Cancer Res 1985: 45: 5252-5256

204. Roldan GE, Gunderson LL, Nagorney GM, Martin JK, Ilstrup DM, Holbrook MA, Kvols LK, McIlrath DC: External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988; 61: 1110-1116.

205. Rose DP: Dietary fatty acids and cancer, Am-J-Clin-Nutr 1997: 66: 998-1003

206. Rose DP: Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies, Am-J-Clin-Nutr 1997: 66: 1513-1522

207. Rose DP, Connolly JM, et al.: Effects of linoleic-acid on the growth and metastasis of two human breast-cancer cell-lines in nude mice and the invasive capacity of these cell-lines in-vitro, Cancer-Res 1994: 54: 6557-6562

208. Rose DP, Conolly JM, et al.: Effects of linoleic acid and g-linolenic acid on the growth and metastasis of a human breast-cancer cell-line in nude-mice and on its growth and invasive capacity in-vitro, Nutr-Cancer 1995: 24: 33-45

209. Rose DP, Connolly JM, et al.: Influence of diets containing EPA or DHA on growth and metastasis of breast-cancer cells in nude mice, J-Natl-Cancer-Inst 1995: 87: 587-592

210. Rose DP, Hatala MA: Dietary fatty acids and breast cancer invasion and metastasis, Nutr-Cancer 1994: 21: 103-111

211. Rosenberg L: Treatment of pancreatic cancer: promises and problems of tamoxifen, somatostatin analogs, and gemcitabine, Int-J-Pancreatol 1997: 22: 81-93

212. Rosenberg L, Barkun AN, et al.: Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas, Cancer 1995: 75: 23-28

[Seite 162↓]

213. Rothman H, Cantrell JE Jr, Lokich J, Difino S, Harvey J, Ahlgren J, Fryer J: Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A mid-atlantic oncology program study. Cancer 1991: 68:

214. Rubin J, Gallagher J, Schutt A, Kuross S, Wieand H: Phase II trials of 5-fluorouracil (5FU) and leucovorin (LV) in patients with metastatic gastric or pancreatic carcinomas. Proc Am Soc Clin 1992: 11: 170

215. Ruch RJ, Klaunig JE: Antioxidant prevention of tumor promoter induced inhibition of mouse hepatocyte intercellular communication. Cancer-Letter 1986; 33: 137-150

216. Roy RS, McCord JM: Superoxide and ischemia: conversion of xanthine dehydrogenase to xanthine oxidase, in: Proceedings of the 3rd international conference on superoxide and superoxide dismutase, ed. by Greenwald R & Cohen G, New York: Elsevier 1983: 145-153

217. Sakagushi M, Imray C, et al. Effects of dietary n-3 and saturated fats on growth-rates of the human colonic-cancer cell-lines SW-620 and LS-174T in vivo, Anticancer-Res 1990: 10: 1763-1768

218. Sakomoto W, Fujie K, Nishihira J, Handa H: Effect of vitamin E on arachidonic acid-release in rat peritoneal macrophages. Biochim Biophys Acta 1993; 1170: 296-300

219. Schally AV: Oncological application for somatostatin analogues, Cancer-Res 1988: 48: 6977-6985

220. Scheithauer W, Pfeffel F, Kornek G, Marczell A, Wiltschke C, Funovics J: A phase II trial of 5-fluorouracil, leucovorin and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 1992: 70: 1864-1866

221. Schimke I, Griesmacher A, et al.: Effects of reactive oxygen species on eicosanoid metabolism in human endothelial cells, Prostaglandins 1992: 43: 281-92

222. Schimke I, Haberland A, et al.: Influence of long-term supplementation with alpha-linolenic acid on myocardial lipid peroxidation and antioxidative capacity in spontaneously hypertensive rats, Prostaglandins-Leukotrienes-Essent-Fatty-Acids 1997: 57: 545-550

223. Schnall SF, MacDonald JS: Chemotherapy of adenocarcinoma of the pancreas, Semin-Oncol 1996: 23: 220-228

[Seite 163↓]

224. Schwager J, Schulze J: Influence of ascorbic acid on the response to mitogens and interleukin production of porcine lymphocytes. Internat-J. Vit-Nutr-Res 1997; 67:

225. Sharma K, Patel YC, et al.: Subtype specific induction of wild type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3, Mol-Endocrinol 1996: 10: 1688-1696

226. Shaughnessy SG, Buchanan MR, et al.: Walker carcinosarcoma cells damage endothelial cells by the generation of reactive oxygen species. Amer-J-Pathol 1989; 134: 787-796

227. Shipley WU, Wood WC, Tepper JE: Intraoperative beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg 1984; 200: 289-294.

228. Sigounas G, Anagnostou A, et al.: a-tocopherol induces apoptosis in erythroleukemia, prostate and breast cancer cells. Nutr-Cancer 1997; 28: 30-35

229. Simmions-Menchaca M, Quian M: RRR-a-tocopheryl succinate inhibits DNA synthesis and enhances the production and secretion of biologically active transforming growth factor-b by avian retrovirus-transformed lymphoid cells. Nutr-Cancer 1995; 24: 171-185

230. Skuladottir GV, Shi Hua D, et al.: Effects of dietary oils and methyl ethyl ketone peroxide on in vivo lipid peroxidation and antioxidants in rat heart and liver, Lipids 1994: 29: 351-357

231. Sporn MB, Roberts AB: Role of retinoids in differentiation and carcinogenesis. Cancer-Res 1983; 43: 3034-3040

232. Szatrowski TP, Nathan CF : Production of large amounts of hydrogen peroxide by human tumor cells. Cancer-Res 1991; 51: 794-798

233. Szepeshazi K, Lapis K, et al.: Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters, Int-J-Cancer 1991: 49: 260-266

[Seite 164↓]

234. Szepeshazi K, Schally AV, et al.: Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters, Cancer-Res 1991: 51: 5980-5986

235. Takahashi M, Furukawa F, et al.: Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine, Carcinogenesis 1990: 11: 393-395

236. Takeda Y, Escribano MJ: Effects of insulin and somatostatin on the growth and the colony formation of two human pancreatic cancer cell lines, J-Cancer-Res-Clin-Oncol 1991: 117: 416-420

237. Tannenbaum SR, Wishnok JS, et al.: Inhibition of nitrosamine formation by ascorbic acid. Am-J-Clin-Nutr 1991; 53: 247S-250S

238. Taragona EM, Pera M, Martinez J, Balague C, Trias M. Laparoscopic treatment of pancreatic disorders: diagnosis and staging, palliation of cancer and treatment of pancreatic pseudocysts. Int Surg 1996; 81(1): 1-5

239. Toyokuni S, Okamoto K, et al.: Persistent oxidative stress in cancer. FEBS-Letters 1995; 358: 1-3

240. Tsuji S, Kawano S, Sawaoka H, Takei Y, Kobayashi I, Nagano K, Fusamoto H, Kamada T: Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins-Leukotrienes-Essent-Fatty-Acids 1996, 55: 179-183

241. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93: 705-716

242. Ulrich-Pur-H, Kornek GV, Raderer M, Haider K, Kwasny W, Depisch D, Greul R, Schneeweiss B, Krauss G, Funovics J, Scheithauer W. A phase II trial of adenocarcinoma. Cancer 2000; 88(11): 2505-11

243. Upp JR, Olson D, et al.: Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS201-995, Am-J-Surg 1988: 155: 29-35

244. Vane JR, Botting RM: Mechanism of action of antiinflammatory drugs. Int-J-Tiss-Reac 1998; 20: 3-15

[Seite 165↓]

245. Vartak S, Robbins MEC, et al.: Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced cell kill, Lipids 1997: 32: 283- 292

246. Verhees S, Flechtner H, Queisser W, Heim ME, Fritz M, Trux F, Edler L: Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II) From the chemotherapy of gastrointestinal tumor group. Onkologie 1990; 13: 50-52.

247. Vezeridis MP, Wanebo HJ: Surgical resection for carcinoma of the pancreas: a historical overview, Semin-Surg-Oncol 1995: 11: 108-113

248. Vidal K, Rauly I, et al.: Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells, Mol-Pharmacol 1994: 46: 97-104

249. Viguerie N, Tahiri-Jouti N, et al.: Direct inhibitory effects of a somatostatin analog, SMS201-995, on AR42J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism, Endocrinol 1989: 124: 1017-1025

250. Wanebo HJ, Kennedy BJ, Chimmel J, Winchester D, Steele G: Survey of patterns of care for gastric cancer in the United States. Proc Am Soc Clin 1992; 11: 166.

251. Wanebo HJ, Vezeridis MP: Pancreatic cancer: an overview, Semin-Surg-Oncol 1995: 11: 168-180

252. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma, N-Engl-J-Med 1992: 326: 455-465

253. Watanapa P, Williamson RC: Experimental pancreatic hyperplasia and neoplasia: effects of dietary and surgical manipulation, Br-J-Cancer 1993: 67: 877-884

254. Waters JS, Ross PJ, et al.: New approaches to the treatment of gastro-intestinal cancer, Digestion 1997: 58: 508-519

255. Weber C, Erl W, et al.: DHA selectively attenuates induction of VCAM-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by TNFa, Arterioscler-Thromb-Vasc-Biol 1995: 15: 622

256. Weinermann B, McCormick R: A phase II survival comparison of patients with pancreatic cancer (TPC), treated with 5-fluorouracil (F) and calcium leucovorin (L) compared to matehed tumor registry. Proc Am Soc Clin 1992: 11: 191

[Seite 166↓]

257. Wenger FA, Kilian M, Jacobi CA, Schimke I, Guski H, Müller JM. Does a-linolenic acid in combination with linoleic acid influence liver metastasis and hepatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamster? Prostaglandins, Leukotrienes and Essential Fatty Acids 2000; 6286): 329-334.

258. Wenger FA , Jacobi CA, et al.: Hormontherapie des postoperativ rezidivierten Pankreascarcinoms mit Octreotid und Tamoxifen. Chirurg 1999: 70: 694-699

259. Wenger FA, Jacobi CA, Kilian M, Dressler H, Guski H, Müller JM. The impact of laparoscopic biopsy of pancreatic lymph nodes with helium and carbon dioxide on port site and liver metastasis in BOP-induced pancreatic cancer in hamster. Clinical & Experimental Metastasis 2000: 18: 11-14

260. Wenger FA, Jacobi CA, Zieren J, Döcke W, Volk HD, Müller JM. Tumor size and lymph node status in pancreatic carcinoma – is there a correlation to the preoperative immune function? Langenbecks Arch Surg 1999: 384(5): 473-8

261. Wenger FA, Kilian M, Achucarro P, Heinicken D, Schimke I, Guski H, Jacobi CA, Müller JM. Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian Hamster. Pancreatology 2001 (angenommen zur Publikation)

262. Wenger FA, Kilian M, Bisevac M, Peter FJ, Schimke I, Guski H, Jacobi CA, Müller JM. Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian Hamsters. Br J Cancer 2001 (review)

263. Wenger FA, Kilian M, Jacobi CA, Schimke I, Guski H, Müller JM. Effects of octreotide on liver metastasis and intrametastatic lipidperoxidation in experimental pancreatic cancer. Oncology 2001, 60(3): 189-288.

264. Wenger FA, Kilian M, Mautsch I, Jacobi CA, Schimke I, Saul G, Guski H, Müller JM. Influence of octreotid and tamoxifen on tumor growth and liver metastasis in N-nitrosobis-2-oxopropylamine-induced pancreatic cancer in Syrian Hamster. Hormone Res 2001; 3: 14-18.

265. Wenger FA, Kilian M, Mautsch I, Jacobi CA, Steiert A, Peter FJ, Guski H, Schimke I, Müller JM. Influence of octreotide on liver metastasis and hepatic lipidperoxidation in BOP-induced pancreatic cancer in Syrian Hamsters. Pancreas 2001 (angenommen zur Publikation)

[Seite 167↓]

266. Wenger FA, Kilian M, Neumann J, Guski H, Schimke I, Müller JM. Effects of antioxidative vitamines A, C and E on liver metastasis and intrametastatic lipidperoxidation in BOP-induced pancreatic cancer in Syrian Hamster. Carcinogenesis (review)

267. Wenger FA, Kilian M, Proske JM, Guski H, Schimke I, Jacobi CA. The impact of laparoscopic biopsy of pancreatic lymph nodes on lipid peroxidation by use of helium and carbon dioxide in BOP-induced pancreatic cancer in hamster. Surgical Endoscopy 2001 (angenommen zur Publikation)

268. Wenger FA, Kilian M, Ridders J, Stahlknecht P, Schimke I, Guski H, Jacobi CA, Müller JM. Influence of antioxidative vitamins A, C and E on lipid- peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Prostaglandines, Leukotriens & Essential fatty acids 2001 (angenommen zur Publikation)

269. Wenger FA, Peter F, Zieren J, Steiert A, Jacobi CA, Müller JM. Prognosis factors in carcinoma of the head of the pancreas. Dig. Surg 2000: 17(1): 29-35

270. Wenger FA, Zieren J, Peter FJ, Jacobi CA, Müller JM. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langenbecks Arch Surg 1999: 384(2): 181-6

271. Willett WC, Hunter DJ: Vitamin A and cancers of the breast, large bowel and prostate: epidemiologic evidence. Nutr-Rev 1994; 52: 53-59

272. Williams CS, DuBois RN: Prostaglandin endoperoxide synthase: Why two isoforms? Am-J-Physiol-Gastrointest-Liver-Physiol 1996, 270: 6393-6400

273. Williams DE, Carpenter HM, et al.: Alterations in lipid peroxidation, antioxidant enzymes and carcinogen metabolism in liver microsomes of vitamin E deficient trout and rat. Toxicol-Pharmacol 1992; 116: 78-84

274. Wolf G: Multiple functions of vitamin A. Physiol-Rev 1984; 64: 873-937

275. Woltering EA, O´Dorisio MS, et al.: The role of radiolabeled somatostatin analogs in the management of cancer patients, in: Principles and practice of oncology: update 1995: 9: 1-16

276. Yang M, Schaich K: Factors affecting DANN damage caused by lipid hydroperoxides and aldehydes. Free-Radic-Biol-Med 1996; 20: 225-236

[Seite 168↓]

277. Yano T, Ishikawa G: Is vitamin E a useful agent to protect against oxy-radical- promoted lung carcinogenesis in ddY mice. Carcinogenesis 1993; 14: 1133-1136

278. Yasui M, Sakamoto J, Yasui K, Morimoto T, Kurimoto K, Kuno N, Morita K: A randomized trial of intraoperative radiation therapy (IORT) vs IORT plus chemotherapy (Mtx-5-FU) for adenocarcinoma of the pancreas. Proc Am Soc Clin 1992; 11: 161.

279. Yeo CJ, Cameron JL: Pancreatic cancer, Curr-Probl-Surg 1999: 36: 67-152

280. Yip-Schneider MT, Barrand DS, Billings SD, Cheng L, Heilmann DK, Lin A, Marshall SJ, Crowell PL, Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21: 139-146

281. Zalatnai A, Schally AV: Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules, Cancer-Res 1989: 49: 1810-1815

282. Zhang L, Mills KJ, et al.: Evidence for the involvement of retinoic acid receptor RAR-dependent signaling pathway in the induction of tissue transglutaminase and apoptosis by retinoids. J-Biolo-Chem 1995; 11: 6022-6029

[Seite 171↓]

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: